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Abstract
The Sonic hedgehog (Shh) signalling pathway plays important roles during development and in 
cancer. Here we report a Shh-induced epigenetic switch that cooperates with Gli to control 
transcription outcomes. Before induction, poised Shh target genes are marked by a bivalent 
chromatin domain containing a repressive histone H3K27me3 mark and an active H3K4me3 mark. 
Shh activation induces a local switch of epigenetic cofactors from the H3K27 methyltransferase 
polycomb repressive complex 2 (PRC2) to an H3K27me3 demethylase Jmjd3/Kdm6b-centred 
coactivator complex. We also find that non-enzymatic activities of Jmjd3 are important and that 
Jmjd3 recruits the Set1/MLL H3K4 methyltransferase complexes in a Shh-dependent manner to 
resolve the bivalent domain. In vivo, changes of the bivalent domain accompanied Shh-activated 
cerebellar progenitor proliferation. Overall, our results reveal a regulatory mechanism that 
underlies the activation of Shh target genes and provides insight into the causes of various diseases 
and cancers exhibiting altered Shh signalling.
Reprints and permission information is available online at http://www.nature.com/reprintsandpermissions/
Correspondence and requests for materials should be addressed to J.W. (jiang9.wu@utsouthwestern.edu). 
Author contributions
J.W, X.S. and Z.Z. designed the experiments. X.S., Z.Z., X.Z., M.C. and J.W. performed the experiments, collected the data and 
analysed the results. T.S., S.A., K.S., T.M., Q.L, R.W, C.W. and K.G. provided critical reagents. J.W. wrote the paper with help from 
all authors.
Accession codes. NCBI SRA SRP047495 for RNA-seq analyses of Shh-responsive genes in MEF cells.
Supplementary Information accompanies this paper at http://www.nature.com/naturecommunications
Competing financial interests: The authors declare no competing financial interests.
HHS Public Access
Author manuscript
Nat Commun. Author manuscript; available in PMC 2017 January 12.
Published in final edited form as:













Sonic hedgehog (Shh) signalling, mediated by Patched and Smoothened, functions as a 
morphogen or a mitogen during many developmental processes1–3. Mutations in the Shh 
pathway components lead to developmental diseases and cancers4,5. Shh signalling produces 
specific transcriptional outcomes by differentially regulating the activities of Gli family 
transcription factors1,2. Under basal conditions, Gli3, and to a lesser extent Gli2, is 
processed to generate a truncated Gli repressor (GliR) that represses basal expression of Shh 
target genes. Shh signalling de-represses and activates target genes by inhibiting Gli3 
processing, inducing Gli3 degradation and activating Gli2/Gli1 transcription activators 
(GliA). The morphogen activity of Shh (for example, in neural tube patterning) is largely 
dependent on its role as an antagonist of GliR function. GliA-mediated transcription 
activation in response to Shh is critical for neural tube progenitor specification in the most 
ventral areas6,7. The mitogenic effects of Shh in many normal and cancer cell types also 
require the GliA activities1,2. For example, Shh/GliA signalling plays a predominant role in 
the proliferation of early postnatal cerebellum granule neuron precursors (CGNPs)8–11. 
Mutations that result in constitutively active Shh signalling cause CGNP overproliferation 
and are the leading genetic causes of the childhood brain tumour medulloblastoma4,5. 
Recent studies suggest a link between active Shh pathways and other cancers, and it appears 
that the oncogenic functions of the Shh pathway require GliA-mediated transcription 
activation1,4.
Despite extensive studies of Hedgehog signalling in multiple organisms, one fundamental 
question remains to be answered: how do Gli proteins de-repress and activate target gene 
expression in response to Shh? Epigenetic factors play critical roles in determining 
transcription outcomes by regulating chromatin structures and accessibilities of DNA to 
transcription machineries. Recently, we identified a Brg1-containing chromatin remodelling 
complex that represses basal expression and activates Shh signalling-induced target gene 
expression12. Interestingly, our results suggest that Brg1 mainly functions as a docking site 
for other chromatin regulators. Brg1 deletion leads to changes in histone modifications in the 
regulatory regions of Shh target genes. Thus, additional histone modifiers may regulate Shh 
signalling, and it is likely that Shh signalling-induced transcription factor exchange from 
GliR to GliA is accompanied by changes of associated epigenetic cofactor complexes to 
produce specific chromatin environments and transcription outcomes.
Bivalent chromatin domains containing both a repressive H3K27me3 and an active 
H3K4me3 mark are found in the regulatory regions of many developmental genes in stem 
cells; these bivalent domains keep gene expression repressed but poised for induction13–16. 
During development, the resolution of the bivalent domain accompanies the activation or 
silencing of the poised genes. The PRC2 complex catalyses the addition of H3K27me3 ref. 
17, whereas the H3K27me3-specific demethylases UTX/Kdm6a and Jmjd3/Kdm6b remove 
it18–22. UTX is also a subunit of H3K4 methyltransferase MLL2/3 complexes20,23, which 
may coordinately activate bivalent genes by removing H3K27me3 and increasing levels of 
H3K4me3. The Jmjd3 catalytic domain shares homology with UTX; however, genetic 
analyses indicate that they play distinct roles during development24–27. Although Jmjd3 does 
not appear to be a subunit of Set1/MLL complexes, it is able to interact with Set1/MLL 
complexes21. The interaction is not strong, and it is not clear whether this interaction plays a 
role in resolving bivalent domains during bivalent gene activation. How bivalent domains are 
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regulated coordinately by epigenetic factors in response to specific developing signals has 
not been well understood.
In this study, we identified a bivalent domain at the regulatory regions of poised Shh target 
genes. Shh signalling induces an epigenetic switch to resolve bivalent domains and activates 
gene expression. PRC2 complexes repress Shh target genes by maintaining the repressive 
H3K27me3 levels, whereas Shh-induced recruitment of Jmjd3 activates target genes by 
displacing PRC2, enzymatically removing H3K27me3 and recruiting Set1/MLL complex. 
The central role of Jmjd3 in regulating Shh-activated gene expression was demonstrated in 
vivo in Shh activation-dependent development and medulloblastoma growth. Our study 
reveals an important epigenetic mechanism underlying the gene activation in response to 
Shh and identifies a potential target to disrupt the mitogenic effect of Shh signalling during 
tumour progression.
Results
Poised Shh-responsive genes are marked by a bivalent domain
To understand the chromatin environment of poised Shh target genes, we analysed the 
publicly available histone modification data obtained from Shh-responsive mouse embryonic 
fibroblast (MEF) cells (Geo data sets GSE21271 (ref. 28)). MEFs as well as NIH3T3 mouse 
fibroblasts express both Gli repressors and activators and are widely used in studies of Shh 
signalling29. Several universal Gli target genes, such as Gli1, Ptch1 and Hhip, are relatively 
restricted to the Shh pathway, and their expression reflects Shh/Gli signalling activities. In 
this screen, we identified an H3K27me3/H3K4me3 bivalent domain in the regulatory 
regions of these Shh target genes (Fig. 1a). The H3K27me3 marks are close to the 
previously identified Gli-binding regions30,31. These regions are close to the promoters and 
may represent proximal enhancers. In contrast, the Shh-independent Gli3 gene was only 
marked with H3K4me3, whereas a silenced neural-specific target gene Olig2 was only 
marked with H3K27me3 (Fig. 1a). We performed an RNA-seq analysis to compare 
expression profiles in wild-type MEFs cultured with or without Shh; expression of 25 genes 
was significantly induced by Shh treatment (P<0.05). Eighteen of these contain the bivalent 
chromatin domain (Supplementary Table 1). Other typical repressive marks, such as 
H3K9me3 and the PRC1-mediated ubiquitinated H2AK119 (refs 32,33), were not present. 
Thus, the poised Shh target genes may be specifically marked by the bivalent chromatin 
domain.
Using Gli1 as a representative Shh target gene, we examined whether the marks in the 
bivalent domain changed with Shh induction. Using chromatin immunoprecipitation (ChIP), 
we found that H3K27me3 was present in the regulatory region of Gli1 gene, and levels were 
significantly reduced on Shh treatment (Fig. 1b). H3K4me3 levels in the Gli1 promoter were 
significantly increased in Shh-treated MEFs (Fig. 1b). Similar changes were observed when 
Gli1 and other Shh target genes were de-repressed in Gli3−/− MEFs or further activated in 
Shh-treated Gli3−/− MEFs (Supplementary Figs 1 and 2). Thus, Gli-mediated Shh target 
gene de-repression and activation are accompanied with the removal of H3K27me3 and 
increase in levels of H3K4me3.
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PRC2 and Jmjd3 are important for Shh target gene expression
To determine whether H3K27me3 reduction is a causal factor in the Shh-mediated gene 
activation, we manipulated the enzymes that add or erase H3K27me3 marks. The PRC2 
complex, which methylates H3K27, contains three essential subunits, EZH2, SUZ12 and 
EED13. RNAi inhibition of SUZ12 expression led to decreased local H3K27me3 levels and 
increased Gli1 basal expression (Fig. 1c). In EZH2−/− MEFs34,35, global H3K27me3 levels 
were decreased and basal expression of Shh target genes such as Gli1 and Ptch1 was 
increased compared with those in wild-type cells (Fig. 1d). Neither Gli2 nor Gli3 expression 
was affected and Olig2 was not de-repressed by EZH2 deletion (Fig. 1d). Only the wild type 
but not an enzymatically inactive mutant EZH2 (F667I)35 rescued the Gli1 expression defect 
(Fig. 1e). These experiments suggest that the PRC2 complex represses basal Shh target gene 
expression by maintaining the H3K27me3 mark. This mechanism also provides a possible 
explanation for the recent findings that EZH2 deletion leads to a de-repression of Shh target 
genes in developing limbs and dorsal hindbrains36,37.
In MEFs lacking Jmjd3 ref. 25, an H3K27me3 demethylase, we observed defects in Shh-
induced gene activation. The activation of several bivalent Shh-responsive genes identified in 
RNA-seq experiments (Supplementary Table 1) was significantly impaired in Jmjd3−/− 
MEFs (Fig. 1f). Jmjd3 deletion resulted in higher local H3K27me3 levels in the Gli1 gene in 
the presence of Shh (Fig. 1g) but not in higher global H3K27me3 levels (Supplementary Fig. 
3), suggesting that Jmjd3 plays a specific role in Shh target gene activation. RNAi inhibition 
of Jmjd3 expression in MEFs phenocopied the Jmjd3−/− defects in Shh-induced Gli1 
expression and local H3K27me3 reduction (Supplementary Fig. 4). Notably, lack of another 
H3K27me3 demethylase, UTX27, did not produce significant effects on Shh-induced target 
gene expression in MEFs (Supplementary Fig. 5). These results indicate that H3K27me3 
and PRC2 are required for the repression of Shh target gene basal expression and that 
erasure of the mark by Jmjd3 in response to Shh is required for gene activation.
Shh induces a local epigenetic switch from PRC2 to Jmjd3
We next monitored the dynamic binding of PRC2 and Jmjd3 in response to Shh signalling. 
In the Gli1 gene, a cluster of Gli-binding sites30,31 overlaps the H3K27me3-enriched region 
(Supplementary Fig. 6A). Using ChIP, we demonstrated that endogenous SUZ12 and, by 
inference, PRC2, binds to Gli1; binding decreased on Shh treatment (Fig. 2a). Conversely, 
ChIP with a Jmjd3 antibody indicated increased binding of Jmjd3 to the Gli1 regulatory 
region on Shh induction (Fig. 2b). A ChIP experiment performed in NIH3T3 cells 
expressing FLAG-tagged Jmjd3 or HA-tagged EZH2 confirmed the binding dynamics: Shh 
treatment reduced EZH2 binding and increased Jmjd3 binding to Gli1 (Supplementary Fig. 
S6). In MEFs, levels of EZH2, SUZ12 and Jmjd3 were similar with or without Shh 
treatment (Fig. 2c,d). Thus, the Shh-induced switch from PRC2 to Jmjd3 in these regulatory 
regions was not due to changes in the global levels of these factors but was likely caused by 
an active recruitment of Jmjd3 to replace PRC2 on Shh stimulation. Indeed, in the absence 
of Jmjd3, a significant amount of SUZ12 remained bound to Gli1 in Shh-treated cells (Fig. 
2a), suggesting that Jmjd3 is required for removal of PRC2 from Shh target genes.
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Shh-induced Gli1/2 activation and binding to target genes may mediate Jmjd3 recruitment. 
Gli2 and Shh-induced Gli1 both can co-immunoprecipitate with Jmjd3 (Fig. 2e,f, 
Supplementary Fig. 7). The exogenous tagged Jmjd3 proteins are expressed in NIH3T3 cells 
at relatively low levels, as it is difficult to detect the full-length Jmjd3 proteins with standard 
western blot. Importantly, RNAi inhibition of Gli1/2 in Shh-treated MEF cultures (Fig. 2g) 
reduced Jmjd3 binding to the Gli1 regulatory region (Fig. 2h) and increased local 
H3K27me3 levels (Fig. 2i), suggesting that Gli1/2 are required for Jmjd3 binding to Shh 
target genes. In contrast, Gli1/2 binding to Shh target genes was not affected by Jmjd3 
deletion (Supplementary Fig. 8). Thus, Gli1/2 activators are required for the recruitment of 
Jmjd3 and possibly other coactivators to displace PRC2 and activate target gene expression. 
To further confirm that Jmjd3 directly regulates Gli-mediated transcription, we expressed 
HA-Gli1 in MEFs and observed that the activation of endogenous Gli target genes by HA-
Gli1 was significantly impaired in Jmjd3−/− MEFs compared with that in wild-type cells 
(Fig. 2j).
Shh-induced switch is essential for target gene expression
To determine whether the Shh-induced, Gli-mediated PRC2 to Jmjd3 switch is required for 
proper target gene expression, we manipulated local PRC2 and Jmjd3 levels to perturb the 
epigenetic switch, either by increasing local PRC2 levels after Shh treatment or introducing 
Jmjd3 onto the Gli1 gene before Shh stimulation. All three Gli proteins contain five 
conserved zinc-fingers that are sufficient to bind specifically to the Gli consensus 
sequence38. We fused the Gli3 DNA binding domain (GliDBD) to HA-tagged EZH2 and 
expressed this fusion in either NIH3T3 cells or MEF cells (Fig. 3a, Supplementary Fig. 9A). 
GliDBD-EZH2 interacted with endogenous SUZ12 as the two proteins were co-
immunoprecipitated (Fig. 3b), suggesting that these proteins form a functional PRC2 
complex. In the presence of Shh, GliDBD-EZH2 can bind Gli1 and increase local 
H3K27me3 levels as shown by ChIP (Fig. 3c,d, Supplementary Fig. 9B,C). Both GliDBD-
EZH2 and exogenous EZH2 reduced Shh-activated Gli1 expression (Fig. 3e, Supplementary 
Fig. 9D). GliDBD-EZH2 repressed Gli1 more effectively and specifically than EZH2; EZH2 
also repressed another Shh-independent target gene HoxA10 (Fig. 3e, Supplementary Fig. 
9D). Thus, increasing the local PRC2 concentration in Shh-stimulated conditions effectively 
repressed Gli1 expression, indicating that PRC2 must be removed to activate gene 
expression. Using similar approaches, we found that GliDBD-Jmjd3 expressed in NIH3T3 
cells (Fig. 3f) bound to the Shh target gene regulatory regions under basal conditions (Fig. 
3g) and decreased local H3K27me3 (Fig. 3h). GliDBD-Jmjd3 activated Shh target genes 
even in the absence of Shh stimulation (Fig. 3i). Thus, recruitment of Jmjd3 is sufficient to 
increase Gli target gene expression before Shh stimulation. These data indicate that the 
presence of PRC2 represses the expression of Shh target genes, whereas the removal of 
PRC2 and the recruitment of Jmjd3 on Shh stimulation activate gene expression. Thus, the 
Shh-induced epigenetic switch from PRC2 to Jmjd3 is essential for target gene activation.
Coordinated target gene activation by Jmjd3 and Set1/MLL
Our results indicate that Jmjd3 is required for the removal of H3K27me3 and activation of 
Shh target genes. It is not clear whether its demethylase activity is essential and/or sufficient 
for this function. The C-terminal fragment of Jmjd3, encompassing the JmjC domain, is 
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sufficient to catalyse H3K27me3 demethylation and rescues several Jmjd3-deficient 
phenotypes21,25. The expression of the C-terminal fragment (aa 1,141–1,641) fused with 
GliDBD (GliDBD-JmjC) was sufficient to reduce local H3K27me3 levels at Gli1 locus (Fig. 
3g,h), but it did not activate Shh target gene basal expression (Fig. 3i). Thus, the Jmjd3 
enzymatic activity alone is not sufficient to activate Shh target genes. We performed rescue 
experiments in NIH3T3 cells co-expressing an shRNA targeting Jmjd3 and exogenous 
RNAi-resistant genes encoding Jmjd3, the JmjC domain, or the Jmjd3-H1388A 
enzymatically inactive proteins21. The cultures were co-transfected with plasmids expressing 
GFP-Gli1 to activate the endogenous Shh target genes (Fig. 4a,b). Although each of these 
Jmjd3 proteins bound to the Gli1 regulatory region (Fig. 4c), only wild-type full-length 
Jmjd3 rescued the defective Gli1-induced gene expression in Jmjd3-knockdown cells (Fig. 
4a), indicating that the demethylase activity is necessary but not sufficient for activation of 
Gli target genes. The non-enzymatic activity of Jmjd3 may serve to recruit other epigenetic 
regulators.
Activation of bivalent genes is accompanied by coordinated changes in levels of both 
H3K27me3 and H3K4me3. Thus, it is likely that Jmjd3 and the Set1/MLL family of 
H3K4me3 methyltransferase complexes function cooperatively to regulate Shh-induced gene 
activation. Ash2L, RbBP5, DPY30 and WDR5 are essential subunits for all Set1/MLL 
family complexes39. RNAi inhibition of expression of individual subunits significantly 
impaired Gli1 expression in Shh-treated NIH3T3 cells (Fig. 4d). To determine whether Shh 
signalling regulates Set1/MLL complex binding to Shh target genes, we performed ChIP 
with WDR5 antibodies. Consistent with the Shh-induced increase of local H3K4me3, the 
binding of endogenous WDR5 to Gli1 and Ptch1 regulatory regions was significantly 
increased on Shh treatment (Fig. 4e). Importantly, in cells deficient in Jmjd3, Shh-induced 
WDR5 binding to target genes and local H3K4me3 increases were significantly impaired 
(Fig. 4e). Consistent with this result, local levels of H3K4me3 in the Gli1 gene in the 
presence of Shh were significantly lower in Jmjd3−/− MEFs than in wild-type cells 
(Supplementary Fig. 10). Thus, Jmjd3 is required for Set1/MLL complexes recruitment to 
target genes in response to Shh stimulation.
It is not clear whether the interaction between Jmjd3 and Set1/MLL complexes21 plays a 
role in resolving bivalent domains; however, our co-immunoprecipitation analyses showed 
that interactions between Jmjd3 and Set1/MLL subunits, WDR5 and ASH2L, were 
significantly enhanced by Shh stimulation (Fig. 4f, Supplementary Fig. 11). The Shh-
induced JmjD3–MLL interaction is potentially phosphorylation-dependent, as treating the 
lysate with λ-phosphatase reduced the interaction to the basal level (Supplementary Fig. 11). 
This result suggests that Shh signalling directly modulates epigenetic complexes required for 
target gene activation. Thus, in addition to the PRC2 to Jmjd3 switch, Shh signalling also 
induces the formation of an epigenetic coactivator complex containing at least Jmjd3 and 
Set1/MLL, which regulates target gene activation coordinately by modulating the bivalent 
domains.
Shi et al. Page 6













Jmjd3−/− mice display Shh-dependent developmental defects
As Jmjd3 is a key factor in Shh-induced epigenetic switch and gene activation, we examined 
its function in Shh-activation-dependent developmental processes. As shown by analysis of 
Gli2−/− mice, Gli2-mediated Shh activation is required for multiple developmental processes 
such as hair follicle development, ventral neural tube patterning and cerebellum progenitor 
proliferation8,40–42. Like Gli2−/− mice, Jmjd3−/− mice die at birth due to respiratory 
failure24,25,43. Interestingly, Jmjd3−/− mice display multiple defects similar to Gli2−/− mice 
in Shh/Gli2-dependent developmental processes.
As a morphogen, Shh is important for neural tube patterning and neural progenitor 
specification. During neural tube development, Shh mainly functions to antagonize GliR 
activity, whereas GliA is only required for the formation of the floor plate and specification 
of the most ventral neural progenitors6,7. Gli2−/− neural tubes display reduced expression of 
markers for floor plate and V3 interneuron progenitors40,41. Jmjd3 is expressed in the ventral 
neural tube but not in the floor plate44. In E10.5 Jmjd3−/− neural tubes, V3 interneuron 
progenitor marker Nkx2.2 levels were significantly reduced (Supplementary Fig. 12A,A
′,C,C′,F) and Olig2-expressing motor neuron progenitor regions were expanded 
(Supplementary Fig. 12B,B′,C,C′,F). These defects are similar to those observed in Gli2−/− 
embryos40. We also observed a reduction of FoxA2 expression in Jmjd3−/− neural tubes but 
not in the floor plate (Supplementary Fig. 12D,D′), possibly due to the absence of Jmjd3 in 
the floor plate or the usage of alternative activation mechanisms. The enriched expression of 
Ptch1 in the most ventral neural tubes was also reduced in Jmjd3−/− embryos 
(Supplementary Fig. 12E,E′). Thus, these results are consistent with a function of Jmjd3 in 
GliA-dependent target gene expression and ventral neural tube development.
Shh-dependent Gli2 activation is essential for embryonic hair follicle development. Gli2−/− 
embryos exhibit an arrest in hair follicle development with reduced cell proliferation42. 
When hair follicles in the sections of E18.5 Jmjd3−/− skin were analysed, we observed 
similarly delayed development of hair follicles. Although both control (wild type and 
Jmjd3+/−) and Jmjd3−/− skins contain hair follicles from all stages45 (stage 1 to 5, 
Supplementary Fig. 13A–D), Jmjd3−/− hair follicles were arrested at earlier developmental 
stages with a peak at stage 2 (Supplementary Fig. 13E). Control hair follicles grew deeper 
and had more mature morphologies with a peak at stage 3 (Supplementary Fig. 13E). This 
defect in Shh/GliA-dependent hair follicle development further corroborates the importance 
of Jmjd3 in Shh signalling activation.
Jmjd3 is required for Shh-dependent CGNP proliferation
During cerebellum development from late embryonic to the early postnatal stage (E18.5–
P14), CGNPs in the external granule layer (EGL) undergo significant expansion and 
differentiation into granule neurons, the most abundant neuron type in the nervous system. 
Multiple signalling pathways and transcription factors coordinate to regulate this process, 
and Shh-mediated Gli activation is necessary for CGNP proliferation9–11. Interestingly, 
during the period from E16.5 to P5, there is a global decrease of H3K27me3 and increase of 
H3K4me3 and H3K27Ac in the cerebellum (Fig. 5a). The decrease of global H3K27me3 
levels was apparent in EGL CGNPs (Fig. 5b) and correlated with the expression of a large 
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amount of genes required for rapid expansion and differentiation of CGNPs at P5. 
Specifically, at Shh target genes, the activation of Gli1 expression at P5 was accompanied by 
a decrease of H3K27me3 and an increase of H3K4me3 (Fig. 5c), which is similar to the 
signalling-induced resolution of the bivalent domain in MEFs. These data suggest that the 
Shh-induced epigenetic switch also occurs in the developing cerebellum to modulate the 
bivalent domain and activate target genes, which contributes to the global change of 
H3K27me3 levels.
Despite the low global level of H3K27me3, EZH2 protein levels remained high in P5 
CGNPs (Fig. 5b), suggesting that a high level of H3K27me3 demethylase activity is present. 
We observed that Jmjd3 expression was increased during cerebellar development from E16.5 
to P4 (Fig. 5d). In P5 cerebellum, Jmjd3 was enriched in EGL (Fig. 5e). Interestingly, at 
E18.5, Jmjd3−/− mice displayed decreased cerebellum size and lack of foliation (Fig. 5f), 
which are similar to the defects observed in the Gli2−/− cerebellum8 and are likely caused by 
impaired CGNP proliferation. To directly determine the function of Jmjd3 in CGNP 
proliferation, we inactivated Jmjd3 using RNAi in Shh-treated P4 CGNP cultures. Reduction 
of Jmjd3 levels in CGNPs significantly impaired the expression of Shh-induced genes such 
as Gli1 and mitogenic Ccnd1 but not other genes such as Brg1 and the CGNP marker Math1 
(Fig. 5g). The proliferation of CGNPs in which Jmjd3 expression was inhibited was 
significantly impaired as shown by the lower BrdU incorporation rates compared with 
control cultures (Fig. 5h). Although neither Shh treatment nor Jmjd3 inhibition in CGNPs 
led to global changes of histone modifications, we observed altered H3K27me3 as well as 
H3K4me3 and H3K27Ac levels at Gli1 regulatory regions in Shh-treated Jmjd3-deficient 
cultures compared with the controls (Fig. 5i–k). A Cre-induced Jmjd3 conditional deletion46 
in CGNP cultures displayed similar defects in Shh target gene expression and altered histone 
modifications (Supplementary Fig. 14). Thus, Jmjd3 regulates Shh-activated gene expression 
and CGNP proliferation by modulating the chromatin environment.
Inhibition of Jmjd3 impairs medulloblastoma cell growth
Mutations leading to constitutively active Shh signalling cause Shh-subtype 
medulloblastoma, the progression of which also requires the active signalling pathway4,47. 
Thus, as a key epigenetic coactivator of Shh target genes, Jmjd3 might be targeted to inhibit 
medulloblastoma growth. We used a mouse model with a Cre-inducible SmoM2 gene (a 
point mutation in Smo) to generate Shh-subtype medulloblastoma48 (Fig. 6a). SmoM2-
induced medulloblastoma cells contain much lower H3K27me3 levels than normal 
cerebellar tissues (Fig. 6b,c). As a significant amount of EZH2 was expressed in SmoM2-
induced medulloblastoma (Fig. 6b–d), the low H3K27me3 levels suggest that H3K27me3 
demethylase is active in these tumour cells. Notably, although Jmjd3 is mutated in some 
cancers and even in non-Shh-type medulloblastoma47,49, it has not been found mutated in 
Shh-type medulloblastoma in several genome-wide exome-sequencing projects47,50–53, 
indicating a potential requirement of Jmjd3 for these tumours.
To determine the function of Jmjd3 in medulloblastoma, we first confirmed that in SmoM2 
medulloblastoma the Gli1 regulatory regions contain lower H3K27me3 levels and higher 
H3K4me3 and H3K27Ac levels than normal cerebellum (Fig. 6e). Reducing Jmjd3 
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expression using virally expressed shRNA significantly impaired the expression of Shh 
target genes such as Gli1, Ptch1, Ccnd1 and N-myc in cultured SmoM2 tumour cells (Fig. 
6f). This defect was not due to the differentiation of tumour cells because the tumour 
progenitor marker Math1 was not significantly reduced (Fig. 6f). Local H3K27me3 levels on 
the Gli1 gene were significantly increased on inhibition of Jmjd3 expression (Fig. 6g). The 
impaired Shh target gene expression in Jmjd3-deficient tumour cells led to a growth 
inhibition similar to that observed in Gli1/2-deficient tumour cultures as indicated by a cell 
survival assay (Fig. 6h). Therefore, as Jmjd3 is required for Shh-subtype medulloblastoma 
growth, Shh-induced epigenetic switching events may be targeted to inhibit 
medulloblastoma growth.
Discussion
In this report, we have identified a bivalent chromatin domain tightly associated with the 
poised states of Shh target genes. We have shown that Shh signalling induces a local 
epigenetic switch as well as the formation of a Jmjd3-centred epigenetic coactivator 
complex, which functions coordinately with GliA to resolve the bivalent domain and to 
activate transcription. We have also demonstrated the essential role of Jmjd3 in regulating 
Shh-dependent developmental processes and tumour proliferation. The epigenetic 
mechanisms elucidated here significantly advance our understanding of Shh signalling and 
provide insights into the mechanisms of Shh-related cancers and diseases.
Activation of Shh signalling induces a local epigenetic switch from PRC2 to Jmjd3 at Shh 
target genes to facilitate the resolution of bivalent chromatin domains. The removal of 
H3K27me3 in response to Shh likely resulted from both the recruitment of Jmjd3 and the 
release of PRC2. We propose that, on Shh signalling stimulation, the activation and binding 
of Gli1/2 mediate the recruitment of Jmjd3 and subsequently the coactivator complex, which 
displaces PRC2 at the regulatory regions, resolves bivalent domains and activates target 
genes (Supplementary Fig. 16). In the absence of Jmjd3, GliA binding was not affected, but 
PRC2 release was impaired and Set1/MLL was not recruited. Although Jmjd3 also functions 
in other pathways, in tissues that are predominantly dependent on GliA function, such as 
embryonic hair follicle, ventral neural tube, cerebellum, and Shh-type medulloblastoma, 
inhibition of Jmjd3 expression and Gli2 deletion led to similar phenotypes. Thus, Jmjd3 
plays an essential role in Shh-induced gene activation by coordinating the changes of 
chromatin environments. Shh signalling also significantly enhances the interactions between 
Jmjd3 and Set1/MLL complexes. Although the biochemical bases for this Shh-induced 
interaction remain unclear, the possibility that Shh signalling directly modifies epigenetic 
cofactors and regulate their activities is intriguing.
Although the experiments were performed in populations of cells and we could not exclude 
the possibility that a fraction of the histone marks may exist in separate cells, our data 
strongly support the coexistence of H3K27me3 and H3K4me3 at the same loci and 
cooperative regulation of both marks by Shh signalling. The Shh-induced interaction 
between Jmjd3 and MLL suggests that they function together to regulate both histone marks. 
Importantly, loss of Jmjd3 not only affected the H3K27me3 levels at Gli target genes, but 
also impaired Shh-induced recruitment of Set1/MLL complexes and increase of H3K4me3 
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levels (Fig. 4f). In CGNPs, loss of Jmjd3 also affected the levels of both histone marks at 
Shh target genes (Fig. 5k). These results could unlikely be explained if the two histone 
marks are in separate cells and regulated independently.
We propose that Shh-induced transcription factor exchange from GliR to GliA triggers the 
switch of the associated epigenetic complexes. Previous work and this report demonstrate 
that a complex epigenetic environment controls Shh target gene expression. It has been 
shown that Shh signalling also functions as switches for several epigenetic regulators that 
may coordinate with PRC2/Jmjd3 to regulate transcription outcomes. We have previously 
reported that Shh activation enables Brg1-containing BAF chromatin remodelling complexes 
to switch from a repressor to an activator state, a switch likely mediated by interacting with 
different Gli transcription factors and other epigenetic regulators12. Brg1 may either 
antagonize or facilitate PRC2 function in a context-dependent manner in embryonic stem 
cell gene expression54. Brg1 has also been shown to interact with Jmjd3 to induce specific 
target gene expression55. Thus, the Brg1 complex may coordinate with these histone 
modifiers to regulate Shh signalling. Indeed, deletion of Brg1 resulted in altered histone 
modifications (ref. 12 and our unpublished data).
In addition, histone deacetylases (HDACs) and histone acetyl transferases (HATs) have been 
directly or indirectly linked to Shh signalling transcription regulation12,56–58. Interestingly, 
Shh signalling activities also alter HDAC function. In basal conditions, HDACs are likely 
involved in repressing the expression of Shh target genes by deacetylating histones12. 
However, on signal activation, HDAC1/2 function as activators of Shh target genes possibly 
by deacetylating and activating Gli1/2 (refs 12,56). HDACs have been shown to tightly 
interact with Brg1 as well as PRC2 complexes12,59. Deletion of the gene encoding PRC2 
subunit EZH2 led to global increase of H3K27Ac35,60 (Supplementary Fig. 15). On Shh 
stimulation, the resolution of the bivalent domain is also accompanied with an increase of 
H3K27Ac at the regulatory regions (Supplementary Fig. 2,). It is not clear whether the 
increased H3K27Ac is a byproduct of H3K27me3 loss or due to active recruitment of the 
H3K27 acetyltransferase p300/CBP60,61. In addition, Jmjd3 has been shown to interact with 
proteins involved in transcription elongation62, which may also function to regulate Shh 
signalling.
During development, Shh can function as a mitogen or a morphogen. For the mitogenic 
function, Shh-induced GliA-mediated transcription activation is required. In this study, we 
demonstrated that during cerebellum development, when active Shh signalling plays an 
essential role in CGNP proliferation, Shh activation is accompanied by a decrease of 
H3K27me3 and an increase of H3K4me3 levels. Shh-subtype medulloblastomas are 
characterized by low levels of H3K27me3. We have shown that a key epigenetic factor 
Jmjd3 is required for the histone modification changes and Shh target gene activation in 
CGNPs and medulloblastoma cells. Deletion of Jmjd3 affects cerebellum growth and CGNP 
proliferation. Inhibiting enzymatic and/or non-enzymatic activities of Jmjd3 may effectively 
inhibit medulloblastoma growth.
In addition to the mitogenic function, Shh also functions as a morphogen to induce dosage-
dependent expression of target genes2. The diverse outputs of Shh signalling are thought to 
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be determined by the combination of activities of GliA and GliR6,7,63. Thus, the 
mechanisms that underlie basal versus signalling-induced conditions identified here might 
also function in more complicated Shh-responsive systems. The morphogenic activities of 
Shh signalling are largely mediated by antagonizing GliR function64,65. We identified PRC2 
as a corepressor of Shh target genes. However, we believe that PRC2 is only part of a 
complex corepressor network associated with GliR. GliA activities are required in the areas 
receiving highest Shh signalling. We also showed modest but significant defects in Jmjd3−/− 
neural tubes in the most ventral area. Recent studies have revealed that the dosage-dependent 
transcription response to Shh results from different affinities for Gli-binding sites, other 
tissue-specific transcription factors, and functional interactions between different target 
genes6,7,63. It is likely that chromatin environment and epigenetic regulators also play 
important roles in determining the transcription outcomes of target genes in response to Shh. 
Additional genetic tools as well as more sensitive ChIP techniques will be needed to directly 
analyse the epigenetic regulation of the complex Shh-responsive systems.
In summary, our study revealed a novel epigenetic mechanism that regulates Shh-induced 
gene activation. We identified Jmjd3 as a key regulator of Shh-activated gene expression and 
Shh-dependent developmental processes and tumour growth. In the future, the 
characterization of the components and analysis of the dynamics of epigenetic complexes 
downstream of Shh signalling will reveal the mechanisms underlying the diverse 
transcription activities of the signalling during development and in diseases.
Methods
Mice
Jmjd3−/− MEFs were produced from E15.5 Jmjd3−/− embryos25. This allele deletes exons 
14–21, which encode a region that includes the JmjC demethylase domain. RT–PCR primers 
Jmjd3_koF1 and Jmjd3_koR1 (Supplementary Information) were used to detect the deletion 
of the Jmjd3 mRNA. E10.5 and E18.5 Jmjd3−/− embryos were produced from mice 
containing a Jmjd3/Kdm6btm1(KOMP)Wtsi allele (Shpargel and Magnuson, unpublished data). 
This allele with exons 11–20 replaced by a Neo cassette was targeted by Knockout Mouse 
Project (KOMP) in JM8 embryonic stem cells of C57BL/6N origin. Embryonic stem cells 
were injected into C57BL/6J-Tyrc-2J/J blastocysts. Following germline transmission, mice 
were maintained on the C57BL/6J background. Homozygotes were generated by 
heterozygous intercrosses. Both Jmjd3 alleles delete a large portion of the protein, and these 
mice die at birth due to respiratory defects, which is similar to the phenotype of another 
Jmjd3 knockout allele24. Both alleles also result in similar skin and cerebellum defects at 
E18.5 and are likely null alleles. Jmjd3 conditional knockout allele was generated as 
previously described with exons 15 to 21 flanked by two LoxP sites46. SmoM2 mice48 and 
CAG-CreER66 mice were purchased from Jackson Laboratory. The SmoM2 CAG-CreER 
mice have a high rate of spontaneous medulloblastoma development before 2 months of age 
(~40%). These mice were maintained on a mixed genetic background at UT Southwestern 
Medical Center Animal Facility.
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Primary MEF, CGNP and medulloblastoma cell cultures
Primary MEFs were cultured from E13.5 to E15.5 embryos as described previously12. In 
brief, embryo trunks were dissected, trypsinized, dissociated to single cells and cultured in 
DMEM media with 10% fetal bovine serum. Primary CGNP cultures were derived from 
dissociated P4 mouse cerebella and cultured in DMEM/F12 media containing 25 mM KCl, 
N2 and 10% FBS. For Shh stimulation, Shh-conditioned medium produced from Shh-CM 
293T cells67 was added at a 1:20 dilution to MEF and CGNP cultures. MEF cells were 
treated with Shh in low-serum media 24 h before harvesting. CGNP cells were treated with 
Shh in high-serum media for 2–3 days. BrdU was added 2 h before analyses. Tumour cells 
were derived from dissociated SmoM2 medulloblastoma and cultured in the media 
containing DMEM/F12, B27, N2, EGF and FGF2.
Plasmid construction, virus preparation and transfection/infection
The shRNA sequences targeting Jmjd3 (5′-AGCACTCGATGCCTCATTCATA)-3′ (ref. 
21), Ash2L (5′-CGAGTCTTGTTAGCCCTACAT-3′), DPY30 (5′-
GCGTTGAGAGAATAGTCGAAA-3′), RbBP5 (5′-GCTCTATTGTATTTACCCATT-3′), 
WDR5 (5′-GCCGTTCATTTCAACCGTGAT-3′), Gli1 (5′-
GCTCAGCTGGTGTGTAATTAC-3′) and Gli2 (5′-CCAACCAGAACAAGCAGAACA-3′) 
were cloned into the PLKO lentiviral vector. The PLKO construct with a scrambled shRNA 
sequence was used as a negative control. Lentiviral vector pSin4-EF2-IRES-Puro was used 
to generate expression constructs for tagged Gli, Jmjd3, Ash2L, WDR5 and EZH2. GliDBD 
fusion proteins were generated by fusing the Gli3 Zinc-finger domains (aa 477–636) with 
EZH2, Jmjd3 full-length protein or the C-terminal fragment including JmjC domain (aa 
1,141–1,641). Lentiviruses were prepared according to a previously described procedure12. 
PolyJet (Signagen) was used for plasmid transfection of cultured cells. Attached cultured 
cells were infected at a multiplicity of infection (MOI) of 5 for 24 h in media with 8 μg ml−1 
polybrene.
RNA-seq
Cultured primary MEFs (second passage) were treated with or without Shh-conditioned 
media for 24 h before harvesting. Total RNAs were extracted, and RNA-seq libraries were 
prepared using Illumina RNA-Seq Preparation Kit and sequenced by an HiSeq 2000 
sequencer. RNA-seq reads were mapped using TopHat with default settings (http://
tophat.cbcb.umd.edu). The mapped reads with the Phred quality score <20 were filtered out, 
whereas the duplicates were marked but not removed using SAMTOOLS68 and PICARD 
(http://picard.sourceforge.net). Transcript assembly and transcript abundance quantification 
were carried out using CUFFLINKS, and then differential expression analysis between Shh-
treated and untreated MEFs was performed using CUFFDIFF69 The differentially expressed 
genes with P<0.05 were selected for histone modification analyses (Supplementary Table 1).
Immunoblotting
For immunoblotting, cells or tissues were lysed in RIPA buffer (50 mM Tris, pH 8, 250 mM 
NaCl, 0.05% SDS, 0.5% DOC, 1% NP-40). Histone fractions were prepared with standard 
acid extraction (0.2 N HCl). Cell lysates or histone fractions were separated on SDS–PAGE 
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(SDS–polyacrylamide gel electrophoresis) gels. Antibodies used were mouse monoclonal 
antibodies against Gli1 (#2643, Cell Signalling), HA (HA-7, Sigma), GAPDH (G9545, 
Sigma), H3K27me3 (#39536, Active Motif), H3H4me3 (ab8580, Abcam), H3K27Ac 
(ab4729, Abcam), histone H3 (ab1791, Abcam), Myc (9E10, Bishop), EZH2 (612667, BD 
Biosciences), SUZ12 (#3737, Cell Signalling) and FLAG (F1804, M2, Sigma). HRP-
conjugated secondary antibodies were purchased from Jackson Immunology. Uncropped 
immunoblots are shown in Supplementary Fig. 17.
Immunohistology and in situ hybridization
Timed mouse pregnancies were determined by plugging date as day 0.5. Haematoxylin and 
eosin (H&E) staining and immunostaining were performed on paraffin sections. Antibodies 
used were against Olig2 (AB9610, Chemicon), NKX2.2 (74.5A5-s, DSHB, University of 
Iowa), FoxA2 (4C7-s, DSHB, University of Iowa), EZH2 (#3737, BD Bioscience), 
H3K4me3 (C42D8, Cell Signaling) and H3K27me3 (07-449, Millipore). The images were 
visualized using an Olympus BX50 microscope. In situ hybridization analyses were 
performed as described previously12 on cryosections (P5 cerebellum) or paraffin sections 
(E10.5 neural tubes). The Ptch1 and Jmjd3 probes correspond to nucleotides (nts) 850–1,637 
and nts 925–1,720 of their cDNAs, respectively.
Co-immunoprecipitation experiments
Antibodies were against the HA-tag (ab9110, rabbit, Abcam) or FLAG-tag (F2426, M2 
beads, Sigma). Shh-responsive NIH3T3 cells were transiently transfected with plasmids 
expressing HA- or FLAG-tagged proteins using PolyJet (Signagen). Mock transfection was 
used as the negative control. Cells were harvested 24–48 h after transfection and were lysed 
with co-IP Lysis Buffer (50 mM Tris, pH 8.0, 150 mM NaCl, 1 mM EDTA, 1% Triton 
X-100, with protease inhibitor freshly added). Cell lysates were snap-frozen in liquid 
nitrogen and then thawed on ice followed by sonication to facilitate cell lysis. After 
centrifugation, appropriate antibodies were added to pre-cleared cell lysate and incubated at 
4 °C overnight. Samples were incubated with protein A beads (GE Healthcare) for 1 h; 
beads were washed with co-IP buffer four times. Precipitated proteins were eluted by boiling 
in 2 × Sample Buffer before SDS–PAGE and western blot analysis. For λ-phosphatase 
treatment, 400 U of enzyme (Sigma) was added to cell lysates followed by 30 min 
incubation at 37 °C.
Chromatin immunoprecipitation
ChIP experiments were performed as described previously12. Dissociated cells were 
crosslinked with PFA or double crosslinked with DSG (Pierce) and PFA, and sonicated to 
fragments (200–1,000 bp). Antibodies used were against H3K27me3 (07-449, Millipore), 
H3K4me3 (ab8580, Abcam), H3K27Ac (ab4729, Abcam), histone H3 (ab1791, Abcam), 
SUZ12 (#3737, Cell Signaling), EZH2 (612667, BD Bioscience), Jmjd3 (ab85392, 
Abcam)70, WDR5 (A302-429A, Bethyl Laboratories), HA (ab9110, Abcam) and FLAG 
(F1804, M2, Sigma). Rabbit IgG was used as a negative control. Precipitated DNA was 
purified and subjected to real-time PCR.
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RNAs from cells or tissues were extracted with TRIZOL (Invitrogen) or the RNeasy kit 
(Qiagen). cDNAs were synthesized by reverse transcription using Superscript III 
(Invitrogen), followed by PCR or quantitative PCR analysis. An ABI-7500 real-time PCR 
system was used for quantitative PCR. Levels of GAPDH mRNA were used to normalize 
input RNA. Graphics shown are representative of experiments performed in triplicate. 
Experiments were repeated for at least three times. Standard errors were calculated 
according to a previously described method12. The primer sequences are listed in the 
Supplementary Information.
Statistical analysis
Data are expressed as means±s.d. Statistical analysis was performed by either analysis of 
variance with ANOVA post hoc t-test for multiple comparisons or a two-tailed unpaired 
Student’s t-test. A P value of <0.05 was considered significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. PRC2 and Jmjd3 regulate Shh target gene expression by modulating the bivalent 
domains
(a) Analyses of ChIP-seq data (Geo datasets GSE21271) showed bivalent domains close to 
transcription start sites of Shh target genes in MEFs. Red and green bars represent the 
chromatin regions enriched for H3K27me3 and H3K4me3, respectively. The 5′ regions of 
the genes are shown as blue lines. Gli3 is not a Shh target gene; Olig2 is a neural-specific 
Shh target gene not expressed in MEFs. (b) Activation of Gli1 by addition of Shh to MEF 
cultures was associated with decreased H3K27me3 and increased H3K4me3 levels in the 
Gli1 regulatory region. The mRNA levels were measured by RT–qPCR, and the ChIP results 
were analysed by ChIP-qPCR. Histone H3 and IgG ChIP were used as histone and antibody 
controls, respectively (means±s.d., n = 3). (c) Reducing SUZ12 levels in MEFs by shRNA 
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treatment led to decreased local H3K27me3 levels and increased Gli1 expression as shown 
by RT–qPCR. Histone H3 ChIP was used for ChIP normalization (means±s.d., n = 3). (d) 
Deletion of EZH2 led to increased basal expression of Gli1 and Ptch1, but not Gli2/3, as 
shown by RT–qPCR (means±s.d., n = 3). (e) Upper panel: exogenous wild-type EZH2, but 
not the F667I mutant, rescued Gli1 expression defects in EZH2−/− MEFs as analysed by RT–
qPCR. Lower panel: western blots show the expression of EZH2 and global H3K27me3 in 
wild-type and EZH2−/− MEFs (means±s.d., n = 3). (f) Wild-type and Jmjd3−/− MEFs were 
treated with Shh. RT–qPCR analyses of Gli1, Ptch1 and other Shh-responsive genes are 
shown (means±s.d., n = 3). (g) Jmjd3 deletion led to higher H3K27me3 levels in the Gli1 
regulatory region in Shh-treated MEFs as shown by ChIP-qPCR. A region upstream of Gli1 
and the CD4 gene were negative controls. Significance was determined using t-test or 
ANOVA with post hoc t-test (means±s.d., n = 3).
** indicates P<0.01 and * indicates P<0.05.
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Figure 2. Shh induces a Gli-dependent local epigenetic switch from PRC2 to Jmjd3
(a) ChIP-qPCR indicates the dynamic binding of endogenous SUZ12 to the Gli1 regulatory 
region in wild-type and Jmjd3−/− MEF cells on Shh induction. (means±s.d., n = 3). (b) 
Increased Jmjd3 binding to Gli1 gene on Shh treatment was shown by ChIP-qPCR (means
±s.d., n = 3). (c) Shh treatment did not reduce levels of PRC2 subunits as shown by EZH2 
and SUZ12 western blot. (d) Jmjd3 expression level was not significantly changed in MEFs 
by Shh treatment as analysed by RT–qPCR (means±s.d., n = 3). (e) Jmjd3 co-
immunoprecipitates with Gli2. Lysates of NIH3T3 cells transiently transfected with 
plasmids expressing HA-Jmjd3 and Myc-Gli2 were immunoprecipitated with anti-HA 
antibodies and blotted with antibodies against HA and Myc. (f) Jmjd3 co-
immunoprecipitates with endogenous Gli1. Cell lysates of Shh-treated NIH3T3 cells 
expressing HA-Jmjd3 were immunoprecipitated with anti-HA antibodies and blotted with 
antibodies against HA and Gli1. (g) RNAi-induced inhibition of Gli1 and Gli2 in Shh-
treated MEFs led to (h) decreased Jmjd3 binding and (i) increased H3K27me3 levels in the 
Gli1 regulatory region (means±s.d., n = 3). (j) Deletion of Jmjd3 in MEFs led to impaired 
endogenous Shh target gene (Gli1, Ptch1, Hhip) expression induced by lentiviral expressed 
HA-Gli1 as shown by RT–qPCR. Expressions of endogenous Gli1 and exogenous HA-Gli1 
were measured using primers specific for the 5′-UTR and the HA tag region, respectively. 
Significance was determined using t-test or ANOVA with post hoc t-test (means±s.d., n = 3). 
** indicates P<0.01 and * indicates P<0.05.
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Figure 3. The Shh-induced local PRC2 to Jmjd3 switch is essential for proper target gene 
expression
(a) Total EZH2 levels in NIH3T3 cells expressing the indicated exogenous proteins as 
shown by western blot with anti-EZH2 antibodies. (b) Exogenous EZH2 and GliDBD-
EZH2, but not GliDBD, expressed in NIH3T3 cells interact with endogenous SUZ12 as 
indicated by IP with an HA antibody and western blot with SUZ12 antibody. All exogenous 
proteins contain an HA tag. (c) GliDBD-EZH2 proteins are recruited to Gli1 regulatory 
region as indicated by ChIP-qPCR with anti-HA antibodies (means±s.d., n = 3). (d) Local 
H3K27me3 levels at Gli1 regulatory region as measured by ChIP-qPCR in Shh-treated 
NIH3T3 cells expressing exogenous proteins (means±s.d., n = 3). (e) RT–qPCR analyses of 
Gli1 and HoxA10 in Shh-treated NIH3T3 cells expressing the indicated exogenous proteins 
(means±s.d., n = 3). (f) Expression of fused Jmjd3 proteins in transfected NIH3T3 cells 
detected by western blot using anti-HA antibodies. The full-length GliDBD-Jmjd3 protein 
band is marked with a star. (g) Binding of HA-tagged GliDBD fusion Jmjd3 proteins and (h) 
local H3K27me3 levels at Gli1 and Ptch1 loci as shown by ChIP-qPCR. Histone H3 ChIP 
was used for normalization (means±s.d., n = 3). (i) RT–qPCR analyses of Gli1, Ptch1 and 
HoxA10 in NIH3T3 cells expressing the indicated exogenous Jmjd3 proteins in basal 
conditions (means±s.d., n = 3). Significance was determined using t-test or ANOVA with 
post hoc t-test; ** indicates P<0.01 and * indicates P<0.05. The comparisons are all against 
the control samples.
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Figure 4. Coordinated functions of Jmjd3 and Set1/MLL regulate Shh-activated gene 
transcription
(a) Both the enzymatic and non-enzymatic activities of Jmjd3 are required for its function in 
Shh-induced gene activation. NIH3T3 cells infected with Jmjd3 shRNA or vector control 
were transfected with plasmids co-expressing GFP-Gli1 and indicated Jmjd3 proteins or 
vector controls. Levels of endogenous Gli1 and Ptch1 were determined by RT–qPCR (means
±s.d., n = 3). (b) Expression of HA-tagged Jmjd3 proteins and exogenous GFP-Gli1 levels in 
transfected cells as detected by western blot. (c) Binding of Jmjd3 and mutants to Gli1 
regulatory region was determined by HA ChIP-qPCR. ‘NS’ indicates not significant (means
±s.d., n = 3). (d) Set1/MLL complexes are important for Shh-induced target gene activation. 
RNAi-mediated inhibition of expression of individual Set1/MLL subunits Ash2L, DPY30, 
RbBP5 and WDR5 significantly impaired Gli1 expression in the presence of Shh as 
measured by RT–qPCR (means±s.d., n = 3). (e) Shh-induced binding of WDR5 to Shh target 
genes requires the presence of Jmjd3. Shown are ChIP-qPCR analyses with antibodies 
against endogenous WDR5 and H3K4me3 in NIH3T3 cells expressing shRNA targeting 
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Jmjd3 or scrambled shRNA in the basal or Shh-treated conditions. CD4 was the negative 
control (means±s.d., n = 3). (f) Shh enhances the interactions between Jmjd3 and Set1/MLL 
subunits. NIH3T3 cells co-transfected with plasmids expressing FLAG-Jmjd3 and HA-
Ash2L were treated with or without Shh. An anti-FLAG antibody was used for 
immunoprecipitation, and antibodies against FLAG or HA were used for western blot. 
Significance was determined using t-test or ANOVA with post hoc t-test; ** indicates 
P<0.01 and * indicates P<0.05. The comparisons are all against the control samples.
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Figure 5. Jmjd3 is required for Shh-dependent CGNP proliferation
(a) Global changes of modified histone levels during cerebellum development evaluated by 
western blot. (b) Immunostaining of sections of E16.5 and P5 cerebella with antibodies 
against modified histones and EZH2. The EGL is the dense cell layer outlining the 
cerebellum. (c) Local changes of H3H27me3 and H3K4me3 at Gli1 regulatory region in 
E16.5 and P5 cerebella (means±s.d., n = 3). (d) RT–qPCR analysis of Jmjd3 in NIH3T3 and 
MEF cells and in cerebellum (CB) and medulloblastoma (MB) samples (means±s.d., n = 3). 
(e) In situ hybridization of P5 CB with Jmjd3 antisense or sense probes. Note the enriched 
Jmjd3 expression in EGL. (f) H&E staining of cerebella from E18.5 wild-type and Jmjd3−/− 
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mice. The average length of EGL per cerebellum section is shown on the right (means±s.d., 
n = 4). (g) Inhibition of Jmjd3 expression in cultured CGNPs results in defective Shh-
induced gene expression as shown by RT–qPCR. (h) Jmjd3 knockdown in cultured CGNPs 
decreases proliferation (as shown by BrdU incorporation) (means±s.d., n = 3). (i) Western 
blots indicating global histone modification levels in CGNP cultures in the absence and 
presence of Shh treatment with or without Jmjd3 shRNA treatment. (j) Immunostaining of 
sections of E18.5 wild-type and Jmjd3−/− cerebella with antibodies against modified 
histones. (k) Decrease in Jmjd3 levels in Shh-treated CGNP cultures by lentiviral-expressed 
shRNA resulted in significant changes of histone modifications at the Gli1 regulatory region 
as shown by ChIP-qPCR. Histone H3 ChIP was used for normalization (means±s.d., n = 3). 
Significance was determined by Student’s t-test; ** indicates P<0.01 and * indicates P<0.05.
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Figure 6. Jmjd3 is required for Shh-subtype medulloblastoma cell growth
(a) H&E staining of sections of a P90 normal cerebellum and one with a SmoM2-induced 
MB. (b) Levels of histone modifications and EZH2 in normal cerebellum (CB) and SmoM2-
induced medulloblastoma (MB) were analysed by immunostaining. IGL = internal granule 
layers. (c) Western blots indicating global levels of histone modifications and EZH2 in 
normal CB and SmoM2 MB. (d) RT–qPCR analysis of EZH2 in NIH3T3 and MEF cells and 
in CB and MB samples (means±s.d., n = 3). (e) ChIP-qPCR analysis of histone modification 
levels in the Gli1 regulatory region in MB and normal CB. Histone H3 ChIP was used for 
ChIP normalization. (means±s.d., n = 3). (f) Cultured SmoM2 medulloblastoma tumour cells 
were infected with lentiviruses expressing either Jmjd3 shRNA or scrambled control. Levels 
of Shh target genes and medulloblastoma progenitor marker Math1 were measured with RT–
qPCR (means±s.d., n = 3). (g) The H3K27me3 level in the Gli1 gene regulatory region was 
increased after inhibition of Jmjd3 expression (means±s.d., n = 3). (h) Cultured SmoM2 
tumour cells were infected with viruses expressing control or shRNA targeting Jmjd3 or 
Gli1/2. The survival rates of cells relative to the control culture were measured using the 
ATP cell viability assay (means±s.d., n = 3). Significance was determined by Student’s t-test 
or ANOVA with post hoc t-test; ** indicates P<0.01 and * indicates P<0.05.
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